A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

PHASE3CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

LY900014

Administered SC

DRUG

Insulin Glargine

Administered SC

Trial Locations (32)

10016

Research NYC, Inc, New York

13210

Suny Health Science Center at Syracuse, Syracuse

20110

Manassas Clinical Research Center, Manassas

20852

Endocrine and Metabolic Consultants, Rockville

21229

Maryland Cardiovascular Specialists, Baltimore

22015

Burke Internal Medicine and Research, Burke

28557

Cataret Medical Group, Morehead City

30318

Atlanta Diabetes Associates, Atlanta

31210

East Coast Institute for Research at The Jones Center, Macon

33021

Encore Medical Research, Hollywood

33401

Metabolic Research Institute, Inc., West Palm Beach

34652

Sun Coast Clinical Research, Inc, New Port Richey

50265

Iowa Diabetes and Endocrinology Research Center, West Des Moines

62711

Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative, Springfield

73069

Intend Research, LLC, Norman

75230

Dallas Diabetes Research Center, Dallas

77043

Biopharma Informatic, LLC, Houston

77079

Endocrine Ips, Pllc, Houston

78231

Consano Clinical Research, LLC, Shavano Park

78749

Texas Diabetes & Endocrinology, P.A., Austin

83404

Rocky Mountain Clinical Research, Idaho Falls

89128

Palm Research Center Tenaya, Las Vegas

89148

Palm Research Center Tenaya, Las Vegas

92025

AMCR Institute, Escondido

92780

University Clinical Investigators, Inc., Tustin

93003

Coastal Metabolic Research Centre, Ventura

93720

Valley Endocrine, Fresno, Fresno

94520

John Muir Physician Network Clinical Research Center, Concord

98057

Rainier Clinical Research Center, Renton

06517

CMR of Greater New Haven, Hamden

00674

Manati Center for Clinical Research Inc, Manatí

00961

Advanced Clinical Research, LLC, Bayamón

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04605991 - A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) | Biotech Hunter | Biotech Hunter